BeyondSpring Inc. (BYSI)
NASDAQ: BYSI · Real-Time Price · USD
1.870
-0.030 (-1.58%)
At close: Dec 18, 2025, 4:00 PM EST
1.810
-0.060 (-3.21%)
After-hours: Dec 18, 2025, 7:44 PM EST
BeyondSpring Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
40
Market Cap
76.90M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 1.35M | - | - |
| Dec 31, 2021 | 1.35M | 1.17M | 650.56% |
| Dec 31, 2020 | 180.00K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
BYSI News
- 6 days ago - BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path - GlobeNewsWire
- 3 months ago - BeyondSpring Inc. (BYSI) 2025 Annual Shareholders Meeting (Transcript) - Seeking Alpha
- 5 months ago - BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure - GlobeNewsWire
- 7 months ago - BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting - GlobeNewsWire
- 7 months ago - BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 months ago - BeyondSpring Files 2024 Annual Report on Form 10-K - GlobeNewsWire
- 11 months ago - BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies - GlobeNewsWire
- 11 months ago - SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors - GlobeNewsWire